{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:15:41Z","timestamp":1789193741000,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Neurosci."],"abstract":"<jats:p>Diverse neurological symptoms have been reported in patients with SARS-CoV-2 disease (COVID-19), including stroke, ataxia, meningitis, encephalitis, and cognitive impairment. These alterations can cause serious sequelae or death and are associated with the entry of SARS-CoV-2 into the Central Nervous System (CNS). This mini-review discusses the main proposed mechanisms by which SARS-CoV-2 interacts with the blood-brain barrier (BBB) and its involvement in the passage of drugs into the CNS. We performed a search in PubMed with the terms \u201cCOVID-19\u201d or \u201cSARS-CoV-2\u201d and \u201cblood-brain barrier injury\u201d or \u201cbrain injury\u201d from the year 2019 to 2022. We found proposed evidence that SARS-CoV-2 infects neurovascular cells and increases BBB permeability by increasing the expression of matrix metalloproteinase-9 that degrades type IV collagen in the basement membrane and through activating RhoA, which induces restructuring of the cytoskeleton and alters the integrity of the barrier. The breakdown of the BBB triggers a severe inflammatory response, causing the cytokine storm (release of IL-1\u03b2, IL-6, TNF-\u03b1, etc.) characteristic of the severe phase of COVID-19, which includes the recruitment of macrophages and lymphocytes and the activation of astrocytes and microglia. We conclude that the increased permeability of the BBB would allow the passage of drugs that would not reach the brain in a normal physiological state, thus enhancing certain drugs\u2019 beneficial or adverse effects. We hope this article will encourage research on the impact of drugs on patients with COVID-19 and recovered patients with sequelae, focusing mainly on possible dose adjustments and changes in pharmacokinetic parameters.<\/jats:p>","DOI":"10.3389\/fncel.2023.1125109","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:31:42Z","timestamp":1678768302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain"],"prefix":"10.3389","volume":"17","author":[{"given":"H\u00e9ctor","family":"Hern\u00e1ndez-Parra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio Daniel","family":"Reyes-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Figueroa-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gonz\u00e1lez-Del Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maykel","family":"Gonz\u00e1lez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila I.","family":"Pe\u00f1a-Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn","family":"Flor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Leyva-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.745789","article-title":"Neuroinflammation and its impact on the pathogenesis of COVID-19.","volume":"8","author":"Almutairi","year":"2021","journal-title":"Front. Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116832","article-title":"Central nervous system manifestations of COVID-19: A systematic review.","volume":"413","author":"Asadi-Pooya","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms.","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-020-00097-7","article-title":"Neurological manifestations of COVID-19&quot; - guideline of the German society of neurology.","volume":"2","author":"Berlit","year":"2020","journal-title":"Neurol Res. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbi.2020.12.031","article-title":"Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier?","volume":"95","author":"Burks","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/biom12070970","article-title":"COVID-19 and parkinsonism: A critical appraisal.","volume":"12","author":"Cavallieri","year":"2022","journal-title":"Biomolecules"},{"key":"B7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/J.FMRE.2022.03.003","article-title":"The blood-brain barrier in health, neurological diseases, and COVID-19.","volume":"2","author":"Chen","year":"2022","journal-title":"Fundam. Res."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.573095","article-title":"The spatial and cell-type distribution of SARS-CoV-2 Receptor ACE2 in the human and mouse brains.","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Neurol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2020.114032","article-title":"Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses.","volume":"289","author":"Chen","year":"2021","journal-title":"J. Virol. Methods"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200960119","article-title":"Morphological, cellular, and molecular basis of brain infection in COVID-19 patients.","volume":"119","author":"Crunfli","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/jir.2014.0227","article-title":"Disease-promoting effects of type I interferons in viral, bacterial, and coinfections.","volume":"35","author":"Davidson","year":"2015","journal-title":"J. Interferon. Cytokine Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s11481-021-10029-0","article-title":"SARS-CoV-2 spike protein disrupts blood-brain barrier integrity via RhoA Activation.","volume":"16","author":"DeOre","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B13","year":"2022","journal-title":"Oseltamivir: Uses, interactions, mechanism of action."},{"key":"B14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.37394\/23208.2022.19.10","article-title":"An Efficient convolutional neural network model for brain MRI segmentation.","volume":"19","author":"el Kader","year":"2022","journal-title":"Wseas Trans. Biol. Biomed."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-021-00116-1","article-title":"Neurological symptoms in COVID-19: A cross-sectional monocentric study of hospitalized patients.","volume":"3","author":"Ermis","year":"2021","journal-title":"Neurol Res. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuarg.2021.05.008","article-title":"Comunicaci\u00f3n entre la periferia y el cerebro en enfermedades neurodegenerativas: Influencia de las citocinas proinflamatorias y su relaci\u00f3n con la COVID-19.","volume":"13","author":"Ferrari","year":"2021","journal-title":"Neurol. Argent."},{"key":"B17","first-page":"112","article-title":"Mechanisms of SARS-CoV-2 entry into neuronal cells and its possible neurological sequelae.","volume":"3","author":"Guiomar-C\u00f3rdova","year":"2021","journal-title":"AMU"},{"key":"B18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01629-8","article-title":"Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions.","volume":"11","author":"Han","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"B20","author":"Jain","year":"2022","journal-title":"Rocuronium"},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination.","volume":"119","author":"Jansen","year":"2019","journal-title":"J. Clin. Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.stemcr.2021.12.011","article-title":"The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2.","volume":"17","author":"Krasemann","year":"2022","journal-title":"Stem Cell Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1002\/jnr.24717","article-title":"Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients.","volume":"98","author":"Kumar","year":"2020","journal-title":"J. Neurosci. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1093\/brain\/awac151","article-title":"Neurovascular injury with complement activation and inflammation in COVID-19.","volume":"145","author":"Lee","year":"2022","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding.","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus Disease 2019 in Wuhan, China.","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"B27","year":"2022","journal-title":"COVID-19 Treatment Guidelines."},{"key":"B28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1248\/yakushi.18-00022","article-title":"[Similarity of clinically significant neuropsychiatric adverse reactions listed in package inserts between the anti-influenza drugs oseltamivir and amantadine (possibility attributable to common pharmacological effects)].","volume":"138","author":"Ono","year":"2018","journal-title":"Yakugaku Zasshi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577590","article-title":"Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2 infection: A case report with long term follow up.","volume":"356","author":"Papri","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and renal tropism of SARS-CoV-2.","volume":"383","author":"Puelles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105608","article-title":"Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system.","volume":"168","author":"Punekar","year":"2022","journal-title":"Microb. Pathog."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1002\/jmv.26149","article-title":"Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.","volume":"92","author":"Quartuccio","year":"2020","journal-title":"J. Med. Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1007\/s00415-020-09866-5","article-title":"CNS penetration of potential anti-COVID-19 drugs.","volume":"267","author":"Richardson","year":"2020","journal-title":"J. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.med.2021.05.005","article-title":"[Role of the immune system in SARS-CoV-2 infection: Immunopathology of COVID-19].","volume":"13","author":"Sanz","year":"2021","journal-title":"Medicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12015-022-10409-w","article-title":"MSC-exosomes carrying miRNA - could they enhance tocilizumab activity in neuropathology of COVID-19?","volume":"19","author":"Schultz","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2538","article-title":"COVID-19 and cognitive impairment: A cross-sectional clinic-based study.","volume":"12","author":"Siddig","year":"2022","journal-title":"Brain Behav."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202135","article-title":"Neuroinvasion of SARS-CoV-2 in human and mouse brain.","volume":"218","author":"Song","year":"2021","journal-title":"J. Exp. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1126\/science.abm2052","article-title":"Nervous system consequences of COVID-19.","volume":"375","author":"Spudich","year":"2022","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13473","article-title":"Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19.","volume":"229","author":"Steardo","year":"2020","journal-title":"Acta Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1348-0421.12945","article-title":"Proteolytic activation of SARS-CoV-2 spike protein.","volume":"66","author":"Takeda","year":"2022","journal-title":"Microbiol. Immunol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-021-01275-3","article-title":"Biological and psychological factors determining neuropsychiatric outcomes in COVID-19.","volume":"23","author":"Tizenberg","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"B43","year":"2020","journal-title":"The History of Pandemics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.928996","article-title":"Long-Term respiratory and neurological sequelae of COVID-19.","volume":"26","author":"Wang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"B45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10787-021-00806-x","article-title":"Neuropathophysiology of coronavirus disease 2019: Neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection.","volume":"29","author":"Welcome","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B46","year":"2022","journal-title":"WHO Coronavirus (COVID-19) Dashboard."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.566680","article-title":"Revisiting the immune balance theory: A neurological insight into the epidemic of COVID-19 and Its Alike.","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/444461","article-title":"Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine mig in pathogenesis.","volume":"41","author":"Xu","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jcrc.2021.07.005","article-title":"Fixed dilated pupils in COVID-19 ARDS patients under rocuronium, reversed after discontinuation.","volume":"65","author":"Zakynthinos","year":"2021","journal-title":"J. Crit. Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00719-9","article-title":"SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration.","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles.","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control Release"},{"key":"B52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.5005\/jp-journals-10071-23592","article-title":"Pathophysiological mechanisms and neurological manifestations in COVID-19.","volume":"24","author":"Zirpe","year":"2020","journal-title":"Indian J. Crit. Care Med."}],"container-title":["Frontiers in Cellular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2023.1125109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:31:47Z","timestamp":1678768307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2023.1125109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":52,"alternative-id":["10.3389\/fncel.2023.1125109"],"URL":"https:\/\/doi.org\/10.3389\/fncel.2023.1125109","relation":{},"ISSN":["1662-5102"],"issn-type":[{"value":"1662-5102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1125109"}}